GE HealthCare has announced an investment of 138 million dollars in the expansion of its plant in Carrigtohill, Cork, Ireland. This project seeks Meet the growing global demand for contrast media used in medical imaging procedures such as computed tomography (CT) scans and X-rays.
With this new facility, the plant will increase its capacity to manage 25 million more doses of contrast medium annually. This expansion is due to begin operating by the end of 2027.
Contrast media are essential for Improve the visualization of organs, blood vessels and tissues during medical imaging proceduresDemand for these products, especially those based on iodine, is increasing due to an ageing population and chronic diseases. It is estimated that the demand for contrast media will double in the next ten years.
Cutting-edge technology and increased capacity
The new 3,000 m² facility will include automated filling lines, powder handling systems and advanced autoclaves. The investment will not only increase production, but also improve the plant's flexibility and resilience to future needs. GE HealthCare has already demonstrated its ability to supply through its plants in Shanghai and Oslo, which together with Cork have supplied more than 100 million doses of contrast media worldwide in 2024.
Kevin O'Neill, President and CEO of GE HealthCare, highlighted the importance of this expansion. “As an industry leader, we have a responsibility to help meet the growing demand for contrast media. This new facility underscores our commitment to supply security and system resilience,” he said.
The Cork facility has been key to GE HealthCare’s global strategy to deliver essential pharmaceutical products to improve healthcare. The company has had a presence in Ireland for over 30 years, and this new investment will strengthen its ability to continue to meet growing demand.
Impact on the community and the economy
The project will also have a positive impact on the local economy, generating more than 250 jobs in the construction phase. In addition, the plant is expected to continue to be a strategic hub for the distribution of contrast media globally. Eugenio Barrett, GE HealthCare Ireland site leader, explained: “We are committed to the future of global health, and this expansion reinforces our key role in providing life-saving treatments.”
The Irish government has also expressed its support for this expansion. An Taoiseach Micheál Martin TD highlighted the importance of the investment for the local economy and employment, noting that this project is a reflection of GE HealthCare's ongoing commitment to Ireland. Michael Loh, CEO of IDA Ireland, also acknowledged the positive impact of the expansion on the country's pharmaceutical sector.
Already a centre of excellence for contrast media manufacturing, the Carrigtohill plant continues to meet the highest standards of Good Manufacturing Practices (GMP)GE HealthCare continues to ensure the quality and safety of its pharmaceutical products for both patients and healthcare providers worldwide.
